Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

Catrin Plumpton; Ana Alfirevic; Munir Pirmohamed; Dyfrig Hughes

doi:10.1093/rheumatology/kex253

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

Catrin Plumpton
, Ana Alfirevic
, Munir Pirmohamed
, Dyfrig Hughes

University of Liverpool

Research output: Contribution to journal › Article › peer-review

233 Downloads (Pure)

Abstract

(ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained.
Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.

Original language	English
Pages (from-to)	1729-1739
Journal	Rheumatology
Volume	56
Issue number	10
Early online date	14 Jul 2017
DOIs	https://doi.org/10.1093/rheumatology/kex253
Publication status	Published - 1 Oct 2017

Access to Document

10.1093/rheumatology/kex253

2017 Cost effectiveness analysisAccepted author manuscript, 957 KB

Cite this

@article{e44bbb93faeb4916950d40960b21cd2f,

title = "Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout",

abstract = "(ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained. Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.",

author = "Catrin Plumpton and Ana Alfirevic and Munir Pirmohamed and Dyfrig Hughes",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/rheumatology/kex253",

language = "English",

volume = "56",

pages = "1729--1739",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

AU - Plumpton, Catrin

AU - Alfirevic, Ana

AU - Pirmohamed, Munir

AU - Hughes, Dyfrig

PY - 2017/10/1

Y1 - 2017/10/1

N2 - (ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained. Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.

AB - (ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained. Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.

U2 - 10.1093/rheumatology/kex253

DO - 10.1093/rheumatology/kex253

M3 - Article

SN - 1462-0324

VL - 56

SP - 1729

EP - 1739

JO - Rheumatology

JF - Rheumatology

IS - 10

ER -

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

Abstract

Access to Document

Fingerprint

Cite this